Abstract
The hepatitis C virus (HCV) is the most common chronic blood-borne infection and the leading cause of liver transplantation in the United States. There are approximately 3.2 million people currently infected with HCV in the United States. In late 2013, the introduction of sofosbuvir and simeprevir represented a critical advancement in the treatment of HCV by improving sustained virologic response (SVR) rates. The purpose of this study was to evaluate medication utilization and clinical outcomes of patients with HCV who were treated with any Food and Drug Administration-approved combination of ribavirin, peginterferon products, simeprevir, and sofosbuvir. Prescription records and clinical assessment forms of patients who started HCV therapy and were eligible for SVR between January 1, 2014, and December 31, 2014, were retrospectively reviewed. Data collection included patient demographics, genotype, SVR, patient-reported adverse events, discontinuations, and adherence markers. A total of 367 eligible patients were identified who had initiated treatment during the study period. Genotype 1 was the most common genotype, and an overall SVR rate of 86.9% was observed. Results were similar to those seen in phase III clinical trials. I...Continue Reading
References
Oct 5, 2001·Lancet·M P MannsJ K Albrecht
Jun 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lisa I BackusLarry A Mole
Nov 21, 2007·Annals of Internal Medicine·Bart J VeldtHarry L A Janssen
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fasiha KanwalSteven M Asch
Sep 22, 2009·Gastroenterology·Maria Grazia RumiMassimo Colombo
Aug 10, 2010·Lancet·Paul Y KwoUNKNOWN SPRINT-1 investigators
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Sep 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for Study of Liver Diseases
Sep 21, 2011·Annals of Internal Medicine·Vincent Lo ReRobert Gross
Jun 27, 2012·Journal of Consulting and Clinical Psychology·Donna M EvonFrancis J Keefe
Apr 24, 2013·The New England Journal of Medicine·Ira M JacobsonUNKNOWN FUSION Study
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
May 29, 2013·Alimentary Pharmacology & Therapeutics·S C GordonK Rajender Reddy
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Mark S SulkowskiUNKNOWN PHOTON-1 Investigators
Aug 1, 2014·Lancet·Eric LawitzIra M Jacobson
Aug 5, 2014·Annals of Internal Medicine·Mina KabiriJagpreet Chhatwal
Citations
May 29, 2019·Journal of Managed Care & Specialty Pharmacy·Marina Amaral de Ávila MachadoSasha Bernatsky
Jul 12, 2017·Open Forum Infectious Diseases·David A WohlKatie R Mollan
Mar 2, 2021·PloS One·Harriet HoMichael R Law